A group of scientists developed a novel strategy using brain-wide genome-editing technology that can reduce Alzheimer's disease (AD) pathologies in genetically modified AD mouse models.
The research was led by international scientists from the Hong Kong University of Science and Technology.
The research technology gives immense potential to be a novel long-run therapeutic treatment for the patients.
The team, led by Professor Nancy, has developed a new genome-editing system that not only crosses the blood-brain barrier but also delivers an optimized genome-editing tool to the entire brain.
During the research it was found that this single-shot has lasting effects and no side effects were detected so far.
The development of the research was published in the journal of Nature Biomedical Engineering.